Microalbuminuria in heart transplant recipients -insights from the randomized trial dapagliflozin for renal protection in heart transplant recipients (DAPARHT)
Event:
ESC Congress 2025
Topic:
Heart Transplantation
Session:
Heart transplantation: risks, markers, and outcomes
Baseline characteristics of the first one hundred and two patients enrolled in the trial DAPAgliflozin for Renal protection in Heart Transplant recipients (DAPARHT)
